EB-0156
EB-0156 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.0479 and less than 0.001 μM, respectively. EB-0156 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0156 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses[1].
Product Specifications
CAS Number
2832824-43-6
UNSPSC
12352005
Target
Glycosidase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/eb-0156.html
Solubility
10 mM in DMSO
Smiles
O[C@@H]1[C@](O)(C[C@@H]([C@@H]([C@H]1O)O)NCCCCCCNC2=C(C=C(C=C2)N3N=CC=N3)[N+]([O-])=O)CO
Molecular Formula
C21H32N6O7
Molecular Weight
480.51
References & Citations
[1]Karade SS, et al. N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. J Med Chem. 2021;64 (24) :18010-18024.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
USC50156-01 50 mg
2- (4-Bromo-3-chloro-2-fluorophenyl) propanoic acid
Sign In for Pricing
View Details USC50156-02 0.5 g
2- (4-Bromo-3-chloro-2-fluorophenyl) propanoic acid
Sign In for Pricing
View Details MBS6443436-02 5x 0.1 mL
WNK3 (With-No-Lysine Kinase 3, PRKWNK3) (AP)
Sign In for Pricing
View Details